Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1990 1
1995 3
1996 2
1997 1
1998 1
1999 2
2000 4
2001 3
2002 4
2003 4
2004 9
2005 2
2006 6
2007 4
2008 4
2009 6
2010 4
2011 2
2012 3
2014 2
2015 4
2016 5
2017 2
2018 4
2019 2
2020 8
2021 2
2022 6
2023 2
2024 2
2025 1

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

94 results

Results by year

Filters applied: . Clear all
Page 1
Darolutamide and Survival in Metastatic, Hormone-Sensitive Prostate Cancer.
Smith MR, Hussain M, Saad F, Fizazi K, Sternberg CN, Crawford ED, Kopyltsov E, Park CH, Alekseev B, Montesa-Pino Á, Ye D, Parnis F, Cruz F, Tammela TLJ, Suzuki H, Utriainen T, Fu C, Uemura M, Méndez-Vidal MJ, Maughan BL, Joensuu H, Thiele S, Li R, Kuss I, Tombal B; ARASENS Trial Investigators. Smith MR, et al. N Engl J Med. 2022 Mar 24;386(12):1132-1142. doi: 10.1056/NEJMoa2119115. Epub 2022 Feb 17. N Engl J Med. 2022. PMID: 35179323 Free PMC article. Clinical Trial.
Erdafitinib or Chemotherapy in Advanced or Metastatic Urothelial Carcinoma.
Loriot Y, Matsubara N, Park SH, Huddart RA, Burgess EF, Houede N, Banek S, Guadalupi V, Ku JH, Valderrama BP, Tran B, Triantos S, Kean Y, Akapame S, Deprince K, Mukhopadhyay S, Stone NL, Siefker-Radtke AO; THOR Cohort 1 Investigators. Loriot Y, et al. N Engl J Med. 2023 Nov 23;389(21):1961-1971. doi: 10.1056/NEJMoa2308849. Epub 2023 Oct 21. N Engl J Med. 2023. PMID: 37870920 Clinical Trial.
Pathological grading for predicting metastasis in phaeochromocytoma and paraganglioma.
Kimura N, Takayanagi R, Takizawa N, Itagaki E, Katabami T, Kakoi N, Rakugi H, Ikeda Y, Tanabe A, Nigawara T, Ito S, Kimura I, Naruse M; Phaeochromocytoma Study Group in Japan. Kimura N, et al. Endocr Relat Cancer. 2014 May 6;21(3):405-14. doi: 10.1530/ERC-13-0494. Print 2014 Jun. Endocr Relat Cancer. 2014. PMID: 24521857
Erdafitinib versus pembrolizumab in pretreated patients with advanced or metastatic urothelial cancer with select FGFR alterations: cohort 2 of the randomized phase III THOR trial.
Siefker-Radtke AO, Matsubara N, Park SH, Huddart RA, Burgess EF, Özgüroğlu M, Valderrama BP, Laguerre B, Basso U, Triantos S, Akapame S, Kean Y, Deprince K, Mukhopadhyay S, Loriot Y; THOR cohort 2 investigators. Siefker-Radtke AO, et al. Ann Oncol. 2024 Jan;35(1):107-117. doi: 10.1016/j.annonc.2023.10.003. Epub 2023 Oct 21. Ann Oncol. 2024. PMID: 37871702 Free article. Clinical Trial.
Cross-sectional and longitudinal analyses of urinary extracellular vesicle mRNA markers in urothelial bladder cancer patients.
Murakami T, Minami K, Harabayashi T, Maruyama S, Takada N, Kashiwagi A, Miyata H, Sato Y, Matsumoto R, Kikuchi H, Abe T, Ito YM, Murai S, Shinohara N, Harada H, Osawa T. Murakami T, et al. Among authors: harabayashi t. Sci Rep. 2024 Mar 21;14(1):6801. doi: 10.1038/s41598-024-55251-x. Sci Rep. 2024. PMID: 38514751 Free PMC article.
[Case of primary leiomyosarcoma of the seminal vesicle].
Suzuki T, Harabayashi T, Abe T, Sazawa A, Shinohara N, Nonomura K. Suzuki T, et al. Among authors: harabayashi t. Nihon Hinyokika Gakkai Zasshi. 2009 Nov;100(7):703-6. doi: 10.5980/jpnjurol.100.703. Nihon Hinyokika Gakkai Zasshi. 2009. PMID: 19999136 Review. Japanese.
Validation of the Japanese version of the Body Image Scale for bladder cancer patients.
Sato M, Osawa T, Abe T, Honda M, Higuchi M, Yamada S, Furumido J, Kikuchi H, Matsumoto R, Sato Y, Sasaki Y, Harabayashi T, Maruyama S, Takada N, Minami K, Tanaka H, Morita K, Kashiwagi A, Murai S, Ito YM, Ogasawara K, Shinohara N. Sato M, et al. Among authors: harabayashi t. Sci Rep. 2022 Dec 13;12(1):21544. doi: 10.1038/s41598-022-25669-2. Sci Rep. 2022. PMID: 36513724 Free PMC article.
Response to: Prognosis of metastatic bone cancer and myeloma patients and long‑term risk of medication‑related osteonecrosis of the jaw (MRONJ): some critical points.
Hata H, Imamachi K, Ueda M, Matsuzaka M, Hiraga H, Osanai T, Harabayashi T, Fujimoto K, Oizumi S, Takahashi M, Yoshikawa K, Sato J, Yamazaki Y, Kitagawa Y. Hata H, et al. Among authors: harabayashi t. Support Care Cancer. 2022 Dec;30(12):9693-9695. doi: 10.1007/s00520-022-07434-3. Epub 2022 Nov 1. Support Care Cancer. 2022. PMID: 36318340 No abstract available.
94 results